Discussion with leaders: Thomas Hope talks with Josh Mailman, an internationally recognized advocate for neuroendocrine tumor patients as well as an advocate for nuclear medicine and molecular imaging.
Page 497
AI algorithm development best practices: Bradshaw and the SNMMI Artificial Intelligence Task Force outline good machine learning practices for algorithm development in nuclear medicine, including standards and recommendations, with specific points relevant to subspecialties.
Page 500
Virtual biopsy: Murray and colleagues look at the concept of virtual biopsies and the likelihood that traditional biopsies can be transformed from physical to virtual while still providing comparable or improved diagnostic and prognostic information.
Page 511
Kinetic analysis: Pantel and colleagues offer the second in a series of educational overviews, here focusing on applications of PET tracer kinetic analysis in oncology, current and future research and clinical implementations, and the future of kinetic modeling.
Page 514
18F-FET PET/MRI in brain tumors: Brendle and colleagues report on the clinical results of multiparametric 18F-FET PET/MRI in patients with brain tumors in a structured, retrospective evaluation of diagnostic performance and impact on clinical management.
Page 522
99mTc-DARPin imaging and HER2: Bragina and colleagues assess the safety, biodistribution, and dosimetry of this radiolabeled small-molecule, small-scaffold protein with picomolar affinity to human epidermal growth factor type 2 in patients with primary breast cancer.
Page 528
68Ga-NOTA-WL12 PET in NSCLC: Zhou and colleagues conduct basic and first-in-humans studies of this agent’s biodistribution, metabolism, dosimetry, safety, and potential for quantifying programmed death ligand-1 expression levels in non–small cell lung cancer.
Page 536
Cost-effectiveness of staging PET in FL: Lo and colleagues report on cost-effectiveness from the perspective of the Canadian health care system of staging PET/CT imaging in early-stage follicular lymphoma before curative-intent radiation treatment.
Page 543
WB-MATV and metabolic response in mCRC: Woff and colleagues validate the prognostic value of 18F-FDG PET/CT–based biomarkers, such as baseline whole-body metabolically active tumor volume and early metabolic response, in patients with metastatic colorectal cancer.
Page 549
TACE + 131I-metuximab in HCC: Chen and colleagues report on a multicenter clinical trial investigating the efficacy and safety of 131I-labeled metuximab plus transcatheter arterial chemoembolization in treatment of unresectable hepatocellular carcinoma.
Page 556
177Lu-PSMA-617 and NOX66 in mCRPC: Pathmanandavel and colleagues document safety and efficacy results of a phase I/II study combining 177Lu-PSMA-617 and a radiosensitizer in patients with metastatic castration-resistant prostate cancer and identify potential clinical, blood-based, and imaging biomarkers.
Page 560
68Ga-PSMA in recurrent PCa: Abghari-Gerst and colleagues detail a prospective investigation of the performance of 68Ga-PSMA-11 PET/CT for detection of prostate adenocarcinoma in a large cohort of patients with elevated levels of prostate-specific antigen after initial therapy.
Page 567
89Zr-PSMA-Df PET/CT in PCa: Dietlein and colleagues research whether this PSMA agent with a longer half-life allows more sensitive detection of weak PSMA-positive prostate cancer lesions.
Page 573
Preclinical and phantom 133La imaging: Nelson and colleagues report on cyclotron production of clinically relevant 133La activities, compare 133La PET phantom imaging with common PET radionuclide imaging, and describe preclinical PET tumor imaging using 133La-PSMA-I&T.
Page 584
Blind restoration digital autoradiogram: Lu and colleagues detail development of a penalized maximum-likelihood expectation–maximization algorithm for improved digital autoradiography resolution, intended to enhance radiotracer and radiotherapy evaluation.
Page 591
Perfusion-only PE screening protocol: Kumar and colleagues assess a pulmonary embolism perfusion-only screening protocol introduced during the COVID-19 pandemic surge.
Page 598
18F-FDG PET and myocardial viability: Mhlanga and colleagues develop a practical protocol for intravenous glucose loading/insulin injection before 18F-FDG administration for PET myocardial viability evaluation in patients with ischemic cardiomyopathy with and without type 2 diabetes.
Page 602
Kinetic analysis of pituitary V1B tracer: Naganawa and colleagues characterize in humans the pharmacokinetic and binding profiles of 11C-TASP699, a novel PET radiotracer with high affinity and selectivity for the vasopressin 1B receptor highly expressed in the pituitary.
Page 609
PET/MRI scanner trial qualification: Catana and a consortium of subject-matter experts propose a path for PET/MRI qualification for brain imaging studies using a patient as a phantom and address key PET/CT accreditation and qualification issues.
Page 615
Fast total-body PET Ki imaging: Wu and colleagues explore 2 new possible protocols for reducing scanning time for whole-body parametric 18F-FDG PET imaging with the uEXPLORER.
Page 622
Antibody distribution and immunoPET: Sharma and colleagues report on the influence of crystallizable fragment modifications and IgG subclass on in vivo biodistribution of antibodies and potential associated effects on molecular imaging development of novel antibody-based theranostic agents.
Page 629
- © 2022 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.